Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance

Lymphatic filariasis is targeted for elimination in India through mass drug administration (MDA) with diethylcarbamazine (DEC) combined with albendazole (ABZ). For the strategy to be effective, >65% of those living in endemic areas must be covered by and compliant to MDA. Post the MDA 2011 campai...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Infectious diseases of poverty 2014-09, Vol.3 (1), p.31-31, Article 31
Hauptverfasser: Hussain, Mohammad A, Sitha, Ashok K, Swain, Subhashisa, Kadam, Shridhar, Pati, Sanghamitra
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 31
container_issue 1
container_start_page 31
container_title Infectious diseases of poverty
container_volume 3
creator Hussain, Mohammad A
Sitha, Ashok K
Swain, Subhashisa
Kadam, Shridhar
Pati, Sanghamitra
description Lymphatic filariasis is targeted for elimination in India through mass drug administration (MDA) with diethylcarbamazine (DEC) combined with albendazole (ABZ). For the strategy to be effective, >65% of those living in endemic areas must be covered by and compliant to MDA. Post the MDA 2011 campaign in the endemic district of Odisha, we conducted a survey to assess: (i) the filariasis knowledge in the community, (ii) the coverage and compliance of MDA from the community perspective, and (iii) factors affecting compliance, as well as the operational issues involved in carrying out MDA activities from the drug distributor's perspective. A sample of 691 participants - both male and female, aged two years or above - were selected through multistage stratified sampling and interviewed using a semi-structured questionnaire. Additionally, drug distributors and the medical officers in charge of the MDA were also interviewed to understand some of the operational issues encountered during MDA. Ninety-nine percent of the study participants received DEC and ABZ tablets during MDA, of which only just above a quarter actually consumed the drugs. The cause of non-compliance was mostly due to fear of side effects, lack of awareness of the benefits of MDA, and non-attendance of health staff in the villages. Lack of adequate training of drug distributors and poor health communication activities before the MDA campaign commenced and the absence of follow-up by health workers following MDA were a few of the operational difficulties encountered during the MDA campaign. Currently MDA is restricted to the distribution of drugs only and the key issues of implementation in compliance, health education, managing side effects, and logistics are not given enough attention. It is therefore essential to address the issues linked to low compliance to make the program more efficient and achieve the goal of filariasis elimination.
doi_str_mv 10.1186/2049-9957-3-31
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4166397</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A541262969</galeid><sourcerecordid>A541262969</sourcerecordid><originalsourceid>FETCH-LOGICAL-b546t-96ff34ed2d8113e228164d2484c87df1f7ac4297dc2172b222bb596d235d88883</originalsourceid><addsrcrecordid>eNp1ksuKFDEUhgtRnGGcrUsJCO5q7JykUhUXQjN4GRhxo-uQyqX7QCppkuqBfgTf2hStzTSOCeR2vvyckz9N85qubigdxHtYcdlK2fUtaxl91lyeDp4va9m1HRVw0VyXguOKAxMgJbxsLqAD1vN-uGx-fdOlEJv3G6LthBHLnPWMKRKfMgmHabetW0M8Bp1RFyzEBazgEcJINDFJl1kHUofZkeTJXbSoP9RImff2QCo36pzR5ULmVPEHl_XGER1t3Uy7gDoa96p54XUo7vrPfNX8_Pzpx-3X9v77l7vb9X07dlzMrRTeM-4s2IFS5gAGKrgFPnAz9NZT32vDQfbWAO1hBIBx7KSwwDo71Maumo9H3d1-nJw1LtaKg9plnHQ-qKRRnUcibtUmPShOhWCyrwLro8CI6T8C55Fao1qcUYsziilGq8bbo8ZGB6cw-lRJM2Exat1xCtUoISt18wRVu3UTmhRddcWdX3j36MLW6TBvSwr7xavypLLJqZTs_Cl9ulLL3_o34TePX-2E__1J7DeNv8tX</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance</title><source>Springer Nature - Complete Springer Journals</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><creator>Hussain, Mohammad A ; Sitha, Ashok K ; Swain, Subhashisa ; Kadam, Shridhar ; Pati, Sanghamitra</creator><creatorcontrib>Hussain, Mohammad A ; Sitha, Ashok K ; Swain, Subhashisa ; Kadam, Shridhar ; Pati, Sanghamitra</creatorcontrib><description>Lymphatic filariasis is targeted for elimination in India through mass drug administration (MDA) with diethylcarbamazine (DEC) combined with albendazole (ABZ). For the strategy to be effective, &gt;65% of those living in endemic areas must be covered by and compliant to MDA. Post the MDA 2011 campaign in the endemic district of Odisha, we conducted a survey to assess: (i) the filariasis knowledge in the community, (ii) the coverage and compliance of MDA from the community perspective, and (iii) factors affecting compliance, as well as the operational issues involved in carrying out MDA activities from the drug distributor's perspective. A sample of 691 participants - both male and female, aged two years or above - were selected through multistage stratified sampling and interviewed using a semi-structured questionnaire. Additionally, drug distributors and the medical officers in charge of the MDA were also interviewed to understand some of the operational issues encountered during MDA. Ninety-nine percent of the study participants received DEC and ABZ tablets during MDA, of which only just above a quarter actually consumed the drugs. The cause of non-compliance was mostly due to fear of side effects, lack of awareness of the benefits of MDA, and non-attendance of health staff in the villages. Lack of adequate training of drug distributors and poor health communication activities before the MDA campaign commenced and the absence of follow-up by health workers following MDA were a few of the operational difficulties encountered during the MDA campaign. Currently MDA is restricted to the distribution of drugs only and the key issues of implementation in compliance, health education, managing side effects, and logistics are not given enough attention. It is therefore essential to address the issues linked to low compliance to make the program more efficient and achieve the goal of filariasis elimination.</description><identifier>ISSN: 2095-5162</identifier><identifier>ISSN: 2049-9957</identifier><identifier>EISSN: 2049-9957</identifier><identifier>DOI: 10.1186/2049-9957-3-31</identifier><identifier>PMID: 25237478</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Drug therapy ; Filariasis ; Pharmaceutical industry ; Surveys</subject><ispartof>Infectious diseases of poverty, 2014-09, Vol.3 (1), p.31-31, Article 31</ispartof><rights>COPYRIGHT 2014 BioMed Central Ltd.</rights><rights>Copyright © 2014 Hussain et al.; licensee BioMed Central Ltd. 2014 Hussain et al.; licensee BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b546t-96ff34ed2d8113e228164d2484c87df1f7ac4297dc2172b222bb596d235d88883</citedby><cites>FETCH-LOGICAL-b546t-96ff34ed2d8113e228164d2484c87df1f7ac4297dc2172b222bb596d235d88883</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4166397/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4166397/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25237478$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hussain, Mohammad A</creatorcontrib><creatorcontrib>Sitha, Ashok K</creatorcontrib><creatorcontrib>Swain, Subhashisa</creatorcontrib><creatorcontrib>Kadam, Shridhar</creatorcontrib><creatorcontrib>Pati, Sanghamitra</creatorcontrib><title>Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance</title><title>Infectious diseases of poverty</title><addtitle>Infect Dis Poverty</addtitle><description>Lymphatic filariasis is targeted for elimination in India through mass drug administration (MDA) with diethylcarbamazine (DEC) combined with albendazole (ABZ). For the strategy to be effective, &gt;65% of those living in endemic areas must be covered by and compliant to MDA. Post the MDA 2011 campaign in the endemic district of Odisha, we conducted a survey to assess: (i) the filariasis knowledge in the community, (ii) the coverage and compliance of MDA from the community perspective, and (iii) factors affecting compliance, as well as the operational issues involved in carrying out MDA activities from the drug distributor's perspective. A sample of 691 participants - both male and female, aged two years or above - were selected through multistage stratified sampling and interviewed using a semi-structured questionnaire. Additionally, drug distributors and the medical officers in charge of the MDA were also interviewed to understand some of the operational issues encountered during MDA. Ninety-nine percent of the study participants received DEC and ABZ tablets during MDA, of which only just above a quarter actually consumed the drugs. The cause of non-compliance was mostly due to fear of side effects, lack of awareness of the benefits of MDA, and non-attendance of health staff in the villages. Lack of adequate training of drug distributors and poor health communication activities before the MDA campaign commenced and the absence of follow-up by health workers following MDA were a few of the operational difficulties encountered during the MDA campaign. Currently MDA is restricted to the distribution of drugs only and the key issues of implementation in compliance, health education, managing side effects, and logistics are not given enough attention. It is therefore essential to address the issues linked to low compliance to make the program more efficient and achieve the goal of filariasis elimination.</description><subject>Drug therapy</subject><subject>Filariasis</subject><subject>Pharmaceutical industry</subject><subject>Surveys</subject><issn>2095-5162</issn><issn>2049-9957</issn><issn>2049-9957</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNp1ksuKFDEUhgtRnGGcrUsJCO5q7JykUhUXQjN4GRhxo-uQyqX7QCppkuqBfgTf2hStzTSOCeR2vvyckz9N85qubigdxHtYcdlK2fUtaxl91lyeDp4va9m1HRVw0VyXguOKAxMgJbxsLqAD1vN-uGx-fdOlEJv3G6LthBHLnPWMKRKfMgmHabetW0M8Bp1RFyzEBazgEcJINDFJl1kHUofZkeTJXbSoP9RImff2QCo36pzR5ULmVPEHl_XGER1t3Uy7gDoa96p54XUo7vrPfNX8_Pzpx-3X9v77l7vb9X07dlzMrRTeM-4s2IFS5gAGKrgFPnAz9NZT32vDQfbWAO1hBIBx7KSwwDo71Maumo9H3d1-nJw1LtaKg9plnHQ-qKRRnUcibtUmPShOhWCyrwLro8CI6T8C55Fao1qcUYsziilGq8bbo8ZGB6cw-lRJM2Exat1xCtUoISt18wRVu3UTmhRddcWdX3j36MLW6TBvSwr7xavypLLJqZTs_Cl9ulLL3_o34TePX-2E__1J7DeNv8tX</recordid><startdate>20140901</startdate><enddate>20140901</enddate><creator>Hussain, Mohammad A</creator><creator>Sitha, Ashok K</creator><creator>Swain, Subhashisa</creator><creator>Kadam, Shridhar</creator><creator>Pati, Sanghamitra</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20140901</creationdate><title>Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance</title><author>Hussain, Mohammad A ; Sitha, Ashok K ; Swain, Subhashisa ; Kadam, Shridhar ; Pati, Sanghamitra</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b546t-96ff34ed2d8113e228164d2484c87df1f7ac4297dc2172b222bb596d235d88883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Drug therapy</topic><topic>Filariasis</topic><topic>Pharmaceutical industry</topic><topic>Surveys</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hussain, Mohammad A</creatorcontrib><creatorcontrib>Sitha, Ashok K</creatorcontrib><creatorcontrib>Swain, Subhashisa</creatorcontrib><creatorcontrib>Kadam, Shridhar</creatorcontrib><creatorcontrib>Pati, Sanghamitra</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Infectious diseases of poverty</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hussain, Mohammad A</au><au>Sitha, Ashok K</au><au>Swain, Subhashisa</au><au>Kadam, Shridhar</au><au>Pati, Sanghamitra</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance</atitle><jtitle>Infectious diseases of poverty</jtitle><addtitle>Infect Dis Poverty</addtitle><date>2014-09-01</date><risdate>2014</risdate><volume>3</volume><issue>1</issue><spage>31</spage><epage>31</epage><pages>31-31</pages><artnum>31</artnum><issn>2095-5162</issn><issn>2049-9957</issn><eissn>2049-9957</eissn><abstract>Lymphatic filariasis is targeted for elimination in India through mass drug administration (MDA) with diethylcarbamazine (DEC) combined with albendazole (ABZ). For the strategy to be effective, &gt;65% of those living in endemic areas must be covered by and compliant to MDA. Post the MDA 2011 campaign in the endemic district of Odisha, we conducted a survey to assess: (i) the filariasis knowledge in the community, (ii) the coverage and compliance of MDA from the community perspective, and (iii) factors affecting compliance, as well as the operational issues involved in carrying out MDA activities from the drug distributor's perspective. A sample of 691 participants - both male and female, aged two years or above - were selected through multistage stratified sampling and interviewed using a semi-structured questionnaire. Additionally, drug distributors and the medical officers in charge of the MDA were also interviewed to understand some of the operational issues encountered during MDA. Ninety-nine percent of the study participants received DEC and ABZ tablets during MDA, of which only just above a quarter actually consumed the drugs. The cause of non-compliance was mostly due to fear of side effects, lack of awareness of the benefits of MDA, and non-attendance of health staff in the villages. Lack of adequate training of drug distributors and poor health communication activities before the MDA campaign commenced and the absence of follow-up by health workers following MDA were a few of the operational difficulties encountered during the MDA campaign. Currently MDA is restricted to the distribution of drugs only and the key issues of implementation in compliance, health education, managing side effects, and logistics are not given enough attention. It is therefore essential to address the issues linked to low compliance to make the program more efficient and achieve the goal of filariasis elimination.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>25237478</pmid><doi>10.1186/2049-9957-3-31</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2095-5162
ispartof Infectious diseases of poverty, 2014-09, Vol.3 (1), p.31-31, Article 31
issn 2095-5162
2049-9957
2049-9957
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4166397
source Springer Nature - Complete Springer Journals; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access; Springer Nature OA Free Journals
subjects Drug therapy
Filariasis
Pharmaceutical industry
Surveys
title Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T22%3A25%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mass%20drug%20administration%20for%20lymphatic%20filariasis%20elimination%20in%20a%20coastal%20state%20of%20India:%20a%20study%20on%20barriers%20to%20coverage%20and%20compliance&rft.jtitle=Infectious%20diseases%20of%20poverty&rft.au=Hussain,%20Mohammad%20A&rft.date=2014-09-01&rft.volume=3&rft.issue=1&rft.spage=31&rft.epage=31&rft.pages=31-31&rft.artnum=31&rft.issn=2095-5162&rft.eissn=2049-9957&rft_id=info:doi/10.1186/2049-9957-3-31&rft_dat=%3Cgale_pubme%3EA541262969%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/25237478&rft_galeid=A541262969&rfr_iscdi=true